These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 21632504

  • 1. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
    Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW.
    J Clin Oncol; 2011 Jul 10; 29(20):2787-94. PubMed ID: 21632504
    [Abstract] [Full Text] [Related]

  • 2. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
    Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL, Tibshirani R, Alizadeh AA, Denney DW.
    J Clin Oncol; 2014 Jun 10; 32(17):1797-803. PubMed ID: 24799467
    [Abstract] [Full Text] [Related]

  • 3. Prolonged idiotypic vaccination against follicular lymphoma.
    Inoges S, Lopez-Diaz de Cerio A, Zabalegui N, Soria E, Villanueva H, Panizo C, Rodriguez-Caballero A, Suarez L, Pastor F, Rodriguez-Calvillo M, Orfao A, Bendandi M.
    Leuk Lymphoma; 2009 Jan 10; 50(1):47-53. PubMed ID: 19152172
    [Abstract] [Full Text] [Related]

  • 4. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.
    Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, Denney DW, Levy R.
    Leuk Lymphoma; 2009 Jan 10; 50(1):37-46. PubMed ID: 19125383
    [Abstract] [Full Text] [Related]

  • 5. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
    Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P.
    J Clin Oncol; 2009 Jun 20; 27(18):3036-43. PubMed ID: 19414675
    [Abstract] [Full Text] [Related]

  • 6. Translational development of vaccination strategies in follicular NHL.
    Sakamaki I, Qin H, Kwak LW.
    Best Pract Res Clin Haematol; 2011 Jun 20; 24(2):295-304. PubMed ID: 21658625
    [Abstract] [Full Text] [Related]

  • 7. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
    Koç ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Carter WD, Gold DP, Stewart ME, Ghalie RG, Bender JF.
    J Immunother; 2010 Jun 20; 33(2):178-84. PubMed ID: 20145546
    [Abstract] [Full Text] [Related]

  • 8. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
    Inogès S, Rodrìguez-Calvillo M, Zabalegui N, Lòpez-Dìaz de Cerio A, Villanueva H, Soria E, Suárez L, Rodríguez-Caballero A, Pastor F, García-Muñóz R, Panizo C, Pèrez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M, Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group, Programa para el Estudio y Tratamiento de Hemopatias Malignas study group.
    J Natl Cancer Inst; 2006 Sep 20; 98(18):1292-301. PubMed ID: 16985248
    [Abstract] [Full Text] [Related]

  • 9. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.
    Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, Pileri A, Boccadoro M, Massaia M.
    Leukemia; 2004 Jan 20; 18(1):139-45. PubMed ID: 14574332
    [Abstract] [Full Text] [Related]

  • 10. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.
    Lee ST, Jiang YF, Park KU, Woo AF, Neelapu SS.
    Expert Opin Biol Ther; 2007 Jan 20; 7(1):113-22. PubMed ID: 17150023
    [Abstract] [Full Text] [Related]

  • 11. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
    Flowers CR.
    Expert Rev Vaccines; 2007 Jun 20; 6(3):307-17. PubMed ID: 17542746
    [Abstract] [Full Text] [Related]

  • 12. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R.
    Blood; 2002 Mar 01; 99(5):1517-26. PubMed ID: 11861263
    [Abstract] [Full Text] [Related]

  • 13. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
    Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, Voena C, Bianchi A, Coscia M, Besostri B, Peola S, Stiefel T, Even J, Novero D, Boccadoro M, Pileri A.
    Blood; 1999 Jul 15; 94(2):673-83. PubMed ID: 10397734
    [Abstract] [Full Text] [Related]

  • 14. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
    Hurvitz SA, Timmerman JM.
    Expert Opin Biol Ther; 2005 Jun 15; 5(6):841-52. PubMed ID: 15952914
    [Abstract] [Full Text] [Related]

  • 15. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
    Neelapu SS, Baskar S, Gause BL, Kobrin CB, Watson TM, Frye AR, Pennington R, Harvey L, Jaffe ES, Robb RJ, Popescu MC, Kwak LW.
    Clin Cancer Res; 2004 Dec 15; 10(24):8309-17. PubMed ID: 15623607
    [Abstract] [Full Text] [Related]

  • 16. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
    Kwak LW, Young HA, Pennington RW, Weeks SD.
    Proc Natl Acad Sci U S A; 1996 Oct 01; 93(20):10972-7. PubMed ID: 8855293
    [Abstract] [Full Text] [Related]

  • 17. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
    Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R.
    J Clin Oncol; 2004 Dec 01; 22(23):4717-24. PubMed ID: 15483014
    [Abstract] [Full Text] [Related]

  • 18. Phase III randomized study of autologous lymphoma-derived idiotype specific vaccination plus GM-CSF in patients with follicular lymphoma in first complete remission.
    Clin Adv Hematol Oncol; 2003 Jan 01; 1(1):67. PubMed ID: 16227966
    [No Abstract] [Full Text] [Related]

  • 19. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.
    Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF.
    J Clin Oncol; 2006 Jul 01; 24(19):3107-12. PubMed ID: 16754937
    [Abstract] [Full Text] [Related]

  • 20. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
    Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R.
    Blood; 1999 Apr 01; 93(7):2411-9. PubMed ID: 10090953
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.